Clinical Trials on PDA in Germany

Total 37 results

W.L.Gore & Associates

Completed

Clinical Investigation of the GORE® Drug-Coated PTA Balloon Catheter (GORE® DCB Catheter) (DCB)

PAD

Germany
International Psychoanalytic University Berlin
Charite University, Berlin, Germany

Terminated

Biological Function of Dreaming in Dreaming and Non-Dreaming Patients With PCA Infarction (BFD)

Dream Disorder | Thrombotic Infarction | PCA Infarct

Germany
Abbott Medical Devices

Completed

Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study (OPTIMIZE BTK)

Vascular Calcification | PAD

Austria, Germany
Medtronic Endovascular

Completed

Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease (INPACT SFA I)

Peripheral Arterial Disease (PAD)

Germany
Michael Lichtenberg, MD

Recruiting

ULTRASCORE™ Focused Force PTA Balloon Angioplasty for CLI Patients With Below the Knee Vessel Disease

Peripheral Arterial Disease (PAD)

Germany
Heinrich-Heine University, Duesseldorf

Not yet recruiting

Mesopancreas Study in Pancreatic Cancer (MESOPANC-01)

Surgery | PDAC | Pancreatoduodenectomy | Margin, Resection | Local Recurrent Tumor

Germany
Bristol-Myers Squibb

Completed

Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants (ALTEA)

Psoriatic Arthritis (PsA)

Germany
Cook Group Incorporated

Completed

Zilver® Flex™ Vascular Stent Study

Peripheral Arterial Disease (PAD)

Germany
University of Erlangen-Nürnberg Medical School

Unknown

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Evaluate Bone Changes in Patients With PsA

Germany
Michael Lichtenberg, MD

Completed

Prestige Pilot - Phoenix Atherectomy and Stellarex DCB Clinical Investigation in Infrapopliteal Interventions

Peripheral Artery Disease (PAD)

Germany
St. Josef Hospital Bochum

Completed

Perioperative Aspirin Response in Patients Undergoing Vascular Surgery

Vascular Surgery Patient With PAD / Carotid Stenosis

Germany
University Hospital Heidelberg
Department of Dermatology, Heidelberg University Hospital

Completed

Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)

Melanoma | Exercise | PD-1 Antibodies

Germany
Cook Group Incorporated

Completed

Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses (XPEDITE)

Peripheral Arterial Disease (PAD)

Germany, New Zealand
Boston Scientific Corporation

Recruiting

Coordinated Reset Deep Brain Stimulation (RESET-DBS)

Parkinson's Disease (PD)

Germany
Gardia Medical

Completed

Evaluation of WIRION™ EPS in Lower Extremities Arteries (WISE-LE)

Peripheral Arterial Disease (PAD)

United States, Germany
Novartis Pharmaceuticals

Completed

Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (PAD PoC)

Peripheral Artery Disease (PAD); Intermittent Claudication

Taiwan, Germany, United States
M.A. Med Alliance S.A.

Completed

First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries

Patients With Peripheral Artery Disease in the SFA or PA

Germany
Novartis Pharmaceuticals

Completed

Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (PRIDE)

Proliferative Diabetic Retinopathy (PDR)

Germany
TriReme Medical, LLC

Active, not recruiting

The Chocolate Touch Study

Ischemia | Intermittent Claudication | Peripheral Artery Disease (PAD)

New Zealand, United States, Austria, Germany
AbbVie

Recruiting

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease (ROSSINI)

Parkinson's Disease (PD)

Germany, Denmark, Spain
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
AbbVie

Completed

Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy (BALANCE)

Parkinson's Disease (PD)

Germany, Switzerland
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
Biogen

Completed

A Real-world Study of Imraldi® Use (PROPER)

Arthritis, Rheumatoid (RA) | Arthritis, Psoriatic (PsA) | Crohn's Disease (CD) | Colitis, Ulcerative (UC) | Axial Spondyloarthritis (axSpA)

Italy, United Kingdom, Germany, Belgium, Spain, Ireland
Adamas Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (EASE LID 3)

Parkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)

France, Spain, United States, Germany, Austria
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
Adamas Pharmaceuticals, Inc.

Completed

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Parkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)

France, Spain, United States, Canada, Germany, Austria
iOMEDICO AG
Roche Pharma AG

Completed

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy (CHAPLIN)

Extensive-stage Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Germany
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation

Clinical Trials on PDA in Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations